AWM
TEVA icon

Able Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Able Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-344
Closed -$3.59K – 523
2023
Q4 		$3.59K Buy
+344
New +$3.21K ﹤0.01% 385

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Able Wealth Management's TEVA Position: Q1 2024 in Review

Able Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2024, closing a stake of 344 shares — an estimated $3.59K sold.

Able Wealth Management first reported a position in TEVA in Q4 2023 and held it in 1 quarter. The position peaked at $3.59K in Q4 2023. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Able Wealth Management reported no remaining Teva Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Able Wealth Management sold 344 Teva Pharmaceuticals shares in Q1 2024, an estimated $3.59K.
  • Able Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Able Wealth Management's Teva Pharmaceuticals position peaked at $3.59K in Q4 2023.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Able Wealth Management's 13F filing for Q1 2024, filed 1 Nov 2024.